BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 15, Issue 21
This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (4354)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.
Item 
Count 
PDF482
HTML3590
Figures (1-1)153
Tables (1-1)129
 Sum=4354
Jun 7, 2009 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin. World J Gastroenterol 2009; 15(21): 2628-2631 [PMID: 19496193 DOI: 10.3748/wjg.15.2628]
URL: https://www.wjgnet.com/1007-9327/full/v15/i21/2628.htm
Number Citing Articles
1
Eamonn M.M. Quigley, Ahmed Abu-Shanab. Small Intestinal Bacterial Overgrowth. Infectious Disease Clinics of North America 2010; 24(4): 943 doi: 10.1016/j.idc.2010.07.007
2
E. Yu. Plotnikova. Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases. Meditsinskiy sovet = Medical Council 2021; (5): 167 doi: 10.21518/2079-701X-2021-5-167-174
3
Sonja Fruhwald, Johann Kainz. Effect of ICU interventions on gastrointestinal motility. Current Opinion in Critical Care 2010; 16(2): 159 doi: 10.1097/MCC.0b013e3283356679
4
Ron Schey, Satish SC Rao. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. Expert Review of Gastroenterology & Hepatology 2011; 5(4): 461 doi: 10.1586/egh.11.50
5
Emmannouil Pyleris, Evangelos J. Giamarellos-Bourboulis, Dimitrios Tzivras, Vassilios Koussoulas, Charalambos Barbatzas, Mark Pimentel. The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome. Digestive Diseases and Sciences 2012; 57(5): 1321 doi: 10.1007/s10620-012-2033-7
6
Tamar Thurm, Yishai Ron. Gastrointestinal Motility Disorders. 2018; : 353 doi: 10.1007/978-3-319-59352-4_32
7
S. K. Zyryanov, E. A. Baybulatova. Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?. Antibiotics and Chemotherapy 2020; 65(7-8): 52 doi: 10.37489/0235-2990-2020-65-7-8-52-62
8
Kichul Yoon, Nayoung Kim, Ju Yup Lee, Dong Hyun Oh, A Young Seo, Chang Yong Yun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee. Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating. The Korean Journal of Gastroenterology 2018; 72(3): 121 doi: 10.4166/kjg.2018.72.3.121
9
V. L. Martynov, A. Kh. Khairdinov. THE ETHIOPATOGENESIS AND THE ANALYSIS OF AN ANTIBIOTIC TREATMENT OF A SMALL INTESTINE BACTERIAL OVERGROWTH SYNDROME. Bulletin of Siberian Medicine 2015; 14(3): 49 doi: 10.20538/1682-0363-2015-3-49-62
10
Mohamad A. Hanouneh, Ibrahim A. Hanouneh, Jana G. Hashash, Ryan Law, Jamak Modaresi Esfeh, Rocio Lopez, Nyla Hazratjee, Thomas Smith, Nizar N. Zein. The Role of Rifaximin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis. Journal of Clinical Gastroenterology 2012; 46(8): 709 doi: 10.1097/MCG.0b013e3182506dbb
11
Hyo Jeong Lee, Jong Kyoung Choi, Han Seung Ryu, Chang Hwan Choi, Eun Hee Kang, Kyung Sik Park, Yang Won Min, Kyoung Sup Hong. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. Journal of Neurogastroenterology and Motility 2017; 23(1): 9 doi: 10.5056/jnm16124
12
Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota. World Journal of Gastroenterology 2023; 29(27): 4236-4251 doi: 10.3748/wjg.v29.i27.4236
13
Francesca Romana Ponziani, Silvia Pecere, Loris Lopetuso, Franco Scaldaferri, Giovanni Cammarota, Antonio Gasbarrini. Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. Expert Opinion on Drug Safety 2016; 15(7): 983 doi: 10.1080/14740338.2016.1186639
14
Sonia Michail, Mun-Wah Ng. Pediatric Neurogastroenterology. 2013; : 49 doi: 10.1007/978-1-60761-709-9_5
15
Péter Varjú, Birgit Ystad, Noémi Gede, Péter Hegyi, Dániel Pécsi, József Czimmer, Elizabeth S. Mayne. The role of small intestinal bacterial overgrowth and false positive diagnosis of lactose intolerance in southwest Hungary—A retrospective observational study. PLOS ONE 2020; 15(5): e0230784 doi: 10.1371/journal.pone.0230784
16
Miles Benardout, Adam Le Gresley, Amr ElShaer, Stephen P. Wren. Fructose malabsorption: causes, diagnosis and treatment. British Journal of Nutrition 2022; 127(4): 481 doi: 10.1017/S0007114521001215
17
A. A. Sheptulin, M. A. Vize-Khripunova. Postinfectious Irritable Bowel Syndrome: Polemic and Open Issues. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2022; 31(6): 41 doi: 10.22416/1382-4376-2021-31-6-41-46
18
Hoonmo L. Koo, Saman Sabounchi, David B. Huang, Herbert L. Dupont. Rifaximin Therapy of Irritable Bowel Syndrome. Clinical Medicine Insights: Gastroenterology 2012; 5: CGast.S7382 doi: 10.4137/CGast.S7382
19
Doron Boltin, Tsachi Tsadok Perets, Einav Shporn, Shoshana Aizic, Sigal Levy, Yaron Niv, Ram Dickman. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Annals of Clinical Microbiology and Antimicrobials 2014; 13(1) doi: 10.1186/s12941-014-0049-x
20
Yehuda Ringel, Tamar Ringel-Kulka. The Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome. Journal of Clinical Gastroenterology 2011; 45: S145 doi: 10.1097/MCG.0b013e31822d32d3
21
Pui Lin Chong, David Laight, Richard J. Aspinall, Antony Higginson, Michael H. Cummings. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01660-5
22
Michel Bouchoucha, Marinos Fysekidis, Céline Lekhal, Bakhtiar Daniel Bejou, Jean-Marc Sabate, Robert Benamouzig. COLIGENTA treatment of small intestinal bacterial overgrowth. Results of an open study.. Digestive and Liver Disease 2021; 53(1): 66 doi: 10.1016/j.dld.2020.10.032
23
Hua Chu, Mark Fox, Xia Zheng, Yanyong Deng, Yanqin Long, Zhihui Huang, Lijun Du, Fei Xu, Ning Dai. Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/3230859
24
A. Uusijärvi, A. Bergström, M. Simrén, J. F. Ludvigsson, I. Kull, M. Wickman, J. Alm, O. Olén. Use of antibiotics in infancy and childhood and risk of recurrent abdominal pain—a Swedish birth cohort study. Neurogastroenterology & Motility 2014; 26(6): 841 doi: 10.1111/nmo.12340
25
Mahmoud Nassar, Victoria Ghernautan, Nso Nso, Akwe Nyabera, Francisco Cuevas Castillo, Wan Tu, Luis Medina, Camelia Ciobanu, Mostafa Alfishawy, Vincent Rizzo, Saphwat Eskaros, Mamdouh Mahdi, Mohamed Khalifa, Mohamed El-Kassas. Gastrointestinal involvement in systemic sclerosis: An updated review. Medicine 2022; 101(45): e31780 doi: 10.1097/MD.0000000000031780
26
Sarah Khan, Lin Chang. Diagnosis and management of IBS. Nature Reviews Gastroenterology & Hepatology 2010; 7(10): 565 doi: 10.1038/nrgastro.2010.137
27
P. Schoenfeld, M. Pimentel, L. Chang, A. Lembo, W. D. Chey, J. Yu, C. Paterson, E. Bortey, W. P. Forbes. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials. Alimentary Pharmacology & Therapeutics 2014; 39(10): 1161 doi: 10.1111/apt.12735
28
Stephen D. H. Malnick, David Fisher, Marina Somin, Manuela G. Neuman. Treating the Metabolic Syndrome by Fecal Transplantation—Current Status. Biology 2021; 10(5): 447 doi: 10.3390/biology10050447
29
Rani H Shayto, Rachel Abou Mrad, Ala I Sharara. Use of rifaximin in gastrointestinal and liver diseases. World Journal of Gastroenterology 2016; 22(29): 6638-6651 doi: 10.3748/wjg.v22.i29.6638
30
Rajan Singh, Hannah Zogg, Lai Wei, Allison Bartlett, Uday C Ghoshal, Singh Rajender, Seungil Ro. Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. Journal of Neurogastroenterology and Motility 2021; 27(1): 19 doi: 10.5056/jnm20149
31
Peter Layer. Handbuch Gastroenterologie 2010. 2010; : 303 doi: 10.1007/978-3-642-11635-3_9
32
Christoph Lübbert. SpringerReference Innere Medizin. 2015; : 1 doi: 10.1007/978-3-642-54676-1_298-1
33
L. Gatta, C. Scarpignato. Systematic review with meta‐analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary Pharmacology & Therapeutics 2017; 45(5): 604 doi: 10.1111/apt.13928
34
Hyun Jik Lee, Kyung Sik Park. Bloating. The Korean Journal of Gastroenterology 2017; 70(6): 288 doi: 10.4166/kjg.2017.70.6.288
35
Ji Min Lee, Chang Nyol Paik, Yeon Ji Kim, Dae Bum Kim, Woo Chul Chung, Kang-Moon Lee, Jin-Mo Yang. The association between a positive lactulose methane breath test and rectocele in constipated patients. Revista Española de Enfermedades Digestivas 2017; 110 doi: 10.17235/reed.2017.5017/2017
36
Dennis Poon, Graham R. Law, Giles Major, H. Jervoise N. Andreyev. A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-05933-1
37
Christoph Lübbert. DGIM Innere Medizin. Springer Reference Medizin 2023; : 1 doi: 10.1007/978-3-642-54676-1_298-2
38
M. Furnari, A. Parodi, L. Gemignani, E. G. Giannini, S. Marenco, E. Savarino, L. Assandri, V. Fazio, D. Bonfanti, S. Inferrera, V. Savarino. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Alimentary Pharmacology & Therapeutics 2010; 32(8): 1000 doi: 10.1111/j.1365-2036.2010.04436.x
39
J. Zhao, X. Zheng, H. Chu, J. Zhao, Y. Cong, M. Fried, M. Fox, N. Dai. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro‐cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterology & Motility 2014; 26(6): 794 doi: 10.1111/nmo.12331
40
Eamonn M.M. Quigley. Yamada' s Textbook of Gastroenterology. 2015; : 1294 doi: 10.1002/9781118512074.ch66
41
Liang Xu, Feng Ji. Infectious Microecology. Advanced Topics in Science and Technology in China 2014; : 293 doi: 10.1007/978-3-662-43883-1_11
42
M. Schmulson, M.V. Bielsa, R. Carmona-Sánchez, A. Hernández, A. López-Colombo, Y. López Vidal, M. Peláez-Luna, J.M. Remes-Troche, J.L. Tamayo, M.A. Valdovinos. Microbiota, infecciones gastrointestinales, inflamación de bajo grado y antibioticoterapia en el síndrome de intestino irritable. Una revisión basada en evidencias. Revista de Gastroenterología de México 2014; 79(2): 96 doi: 10.1016/j.rgmx.2014.01.004
43
Uday C Ghoshal, Abhimanyu Nehra, Akash Mathur, Sushmita Rai. A meta‐analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome. Journal of Gastroenterology and Hepatology 2020; 35(6): 922 doi: 10.1111/jgh.14938
44
Matthew Bohm, Robert M. Siwiec, John M. Wo. Diagnosis and Management of Small Intestinal Bacterial Overgrowth. Nutrition in Clinical Practice 2013; 28(3): 289 doi: 10.1177/0884533613485882
45
Gaurav Ghosh, Arun B. Jesudian. Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis. Journal of Clinical and Experimental Hepatology 2019; 9(2): 257 doi: 10.1016/j.jceh.2018.08.006
46
A Young Seo, Nayoung Kim, Dong Hyun Oh. Abdominal Bloating: Pathophysiology and Treatment. Journal of Neurogastroenterology and Motility 2013; 19(4): 433 doi: 10.5056/jnm.2013.19.4.433
47
Max Schmulson, María Victoria Bielsa, Ramón Carmona-Sánchez, Angélica Hernández, Aurelio López-Colombo, Yolanda López Vidal, Mario Peláez-Luna, José María Remes-Troche, José Luis Tamayo, Miguel Angel Valdovinos. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review. Revista de Gastroenterología de México (English Edition) 2014; 79(2): 96 doi: 10.1016/j.rgmxen.2014.01.001
48
Jing Liu, Lingyu Jiang, Jingju Zhang, Huili Huang, Xiubo Li, Fei Xu. Residue of Rifaximin in Milk of Lactating Dairy Cows Following Administration of Intrauterine Infusion. IOP Conference Series: Earth and Environmental Science 2021; 697(1): 012001 doi: 10.1088/1755-1315/697/1/012001
49
Dietmar Enko, Gabriele Halwachs-Baumann, Robert Stolba, Harald Mangge, Gernot Kriegshäuser. Refining small intestinal bacterial overgrowth diagnosis by means of carbohydrate specificity: a proof-of-concept study. Therapeutic Advances in Gastroenterology 2016; 9(3): 265 doi: 10.1177/1756283X15621231
50
Soraia Tahan, Lígia Cristina F.L. Melli, Carolina Santos Mello, Mírian Silva C. Rodrigues, Humberto Bezerra Filho, Mauro B. de Morais. Effectiveness of Trimethoprim‐Sulfamethoxazole and Metronidazole in the Treatment of Small Intestinal Bacterial Overgrowth in Children Living in a Slum. Journal of Pediatric Gastroenterology and Nutrition 2013; 57(3): 316 doi: 10.1097/MPG.0b013e3182952e93
51
Francesca Romana Ponziani, Viviana Gerardi, Antonio Gasbarrini. Diagnosis and treatment of small intestinal bacterial overgrowth. Expert Review of Gastroenterology & Hepatology 2016; 10(2): 215 doi: 10.1586/17474124.2016.1110017
52
Rosario Cuomo, Giovanni Barbara, Bruno Annibale. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease 2017; 49(6): 595 doi: 10.1016/j.dld.2017.01.164
53
Emily Schwartz, Luigi Brunetti, Jane Ziegler. Antibiotic Treatment of Small Intestinal Bacterial Overgrowth. Topics in Clinical Nutrition 2016; 31(4): 296 doi: 10.1097/TIN.0000000000000081
54
Uday C. Ghoshal, Ratnakar Shukla, Ujjala Ghoshal. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut and Liver 2017; 11(2): 196 doi: 10.5009/gnl16126
55
Natalia Zeber-Lubecka, Maria Kulecka, Filip Ambrozkiewicz, Agnieszka Paziewska, Krzysztof Goryca, Jakub Karczmarski, Tymon Rubel, Wojciech Wojtowicz, Piotr Mlynarz, Lukasz Marczak, Roman Tomecki, Michal Mikula, Jerzy Ostrowski. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes 2016; 7(5): 397 doi: 10.1080/19490976.2016.1215805
56
Yehuda Ringel, Nitsan Maharshak. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology 2013; 305(8): G529 doi: 10.1152/ajpgi.00207.2012
57
Paul Andrew Muller, Balázs Koscsó, Gaurav Manohar Rajani, Korey Stevanovic, Marie-Luise Berres, Daigo Hashimoto, Arthur Mortha, Marylene Leboeuf, Xiu-Min Li, Daniel Mucida, E. Richard Stanley, Stephanie Dahan, Kara Gross Margolis, Michael David Gershon, Miriam Merad, Milena Bogunovic. Crosstalk between Muscularis Macrophages and Enteric Neurons Regulates Gastrointestinal Motility. Cell 2014; 158(2): 300 doi: 10.1016/j.cell.2014.04.050
58
Herbert L DuPont. Biologic properties and clinical uses of rifaximin. Expert Opinion on Pharmacotherapy 2011; 12(2): 293 doi: 10.1517/14656566.2011.546347
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345